Adaptive Biotechnologies

Q2 FY2026 EarningsQ2 FY26 outperformed consensus on the top line with revenue of $71.6M vs. $65.5M expected, a 9.32% beat driven by a 43% surge in clonoSEQ test volumes. Despite the revenue beat, GAAP EPS of -$0.25 missed the -$0.13 mean estimate significantly due to a $23.7M one-time loss on debt extinguishment. Excluding this special item, operational performance showed strength with Adjusted EBITDA improving to -$0.7M and MRD segment profitability expanding as the company pivots toward a potential business separation.